Akero Sees Across-The-Board NASH Benefit With Efruxifermin, But Faces Competition

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

At EASL 2021, Akero presented efruxifermin data showing benefit in cirrhotic NASH patients and strong liver fat reduction, but may be challenged in the FGF21 analog class by 89Bio.

Competitive edge and business advantage concept as a group of hot air balloons racing to the top but an individualleader with a small balloon attached giving the winning competitor an extra boost.
Akero hopes to stay ahead of other FGF21 analogs in NASH

Akero Therapeutics, Inc. bolstered the profile of its FGF21 analog efruxifermin (EFX) as a noteworthy contender in non-alcoholic steatohepatitis during the recently concluded European liver meeting by showing potential benefit in cirrhotic patients and strong liver fat reduction data. While Madrigal Pharmaceuticals, Inc.’s thyroid receptor beta (THRβ) agonist resmetirom exited the meeting as the presumed clinical development leader in NASH, with pivotal Phase III data expected during the second half of 2022, EFX was cited by one analyst as the other NASH candidate that impressed.

[Sidebar#SC144612]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.